Novel Pyrroloquinazolines as Anti-cancer Agents
OHSU # 1851
Novel and Effective Compounds for Triple Negative Breast Cancer
Researchers at Oregon Health & Science University have discovered a novel lead compound that is active against triple negative breast cancer through what is believed to be a novel (unknown at this point-target identification underway) mechanism of action. The lead compound is not cytotoxic and represents a tremendous opportunity to develop the first selective drug for treatment of triple negative breast cancer. This intellectual property provides a platform for a drug development program focused on lead optimization of novel compounds acting under a novel mechanism of action.
United States Non-Provisional patent and PCT patent applications filed.
Investigator: Xiangshu Xiao, PhD
OHSU Technology 1851 is available for exclusive and non-exclusive licensing and/or collaborative co-development.
If interested in learning more, please contact Travis Cook, Senior Technology Development Manager at firstname.lastname@example.org or (503) 494-5861 and reference Tech Id No. 1851.
- Xiangshu Xiao, SM.Physiology & Pharmacology
- Jingjin Chen, SM.Physiology & Pharmacology
- Bingbing Li, SM.Physiology & Pharmacology
|Published||Patent Cooperation Treaty||WO 2014/205272|
For more information, contact:
Senior Technology Development Manager